Multi-Parametric MRI and PET Imaging Improve Accuracy of Prostate Cancer Biopsies
By MedImaging International staff writers Posted on 25 Jul 2016 |
Image: The graphic shows Gleason 3+4 prostate cancer in T2-weighted (A) and diffusion-weighted (B) MRI images. Graphic (C) shows F-18-choline PET, and graphic (D) shows PET/MRI (D) (Photo courtesy of the University of Michigan).
Researchers have demonstrated that a combination of PET and multi-parametric MR imaging can improve targeted prostate cancer biopsies.
The study was published in the July 2016 issue of The Journal of Nuclear Medicine and found that adding F-18-choline Positron Emission Tomography (PET) molecular imaging to multi-parametric Magnetic Resonance Imaging (mpMRI) improves the chance of recognizing significant prostate cancer during targeted trans-rectal prostate biopsies.
The study, part of an ongoing prospective clinical trial was carried out by researchers at the University of Michigan (UMS; Ann Arbor, MI, USA) and included 36 subjects of which 15 were eventually identified with significant prostate cancer. The researchers concluded that image registration using fusion PET imaging together with MRI real-time Trans-Rectal Ultrasound (TRUS) during targeted prostate biopsies was accurate and clinically feasible. The addition of F-18-choline PET, to the mpMRI procedure resulted in improved identification of significant prostate cancer.
Morand Piert, MD, radiology professor, Division of Nuclear Medicine, University of Michigan, said, "Our positive results suggest that in the future, PET/MRI may become a one-stop imaging test for men with suspected but undetected prostate cancer or for patients undergoing surveillance for known low-risk prostate cancer. Since prostate cancer is often multi-focal and presents with multiple lesions of varying risk, it is important to identify the lesions that harbor the greatest malignant potential. Accurate identification of clinically significant cancer and avoidance of clinically insignificant cancer is the centerpiece of modern prostate cancer diagnosis. The use of advanced imaging to inform placement of biopsy needles promises to greatly minimize the uncertainty associated with prostate cancer care."
Related Links:
University of Michigan
The study was published in the July 2016 issue of The Journal of Nuclear Medicine and found that adding F-18-choline Positron Emission Tomography (PET) molecular imaging to multi-parametric Magnetic Resonance Imaging (mpMRI) improves the chance of recognizing significant prostate cancer during targeted trans-rectal prostate biopsies.
The study, part of an ongoing prospective clinical trial was carried out by researchers at the University of Michigan (UMS; Ann Arbor, MI, USA) and included 36 subjects of which 15 were eventually identified with significant prostate cancer. The researchers concluded that image registration using fusion PET imaging together with MRI real-time Trans-Rectal Ultrasound (TRUS) during targeted prostate biopsies was accurate and clinically feasible. The addition of F-18-choline PET, to the mpMRI procedure resulted in improved identification of significant prostate cancer.
Morand Piert, MD, radiology professor, Division of Nuclear Medicine, University of Michigan, said, "Our positive results suggest that in the future, PET/MRI may become a one-stop imaging test for men with suspected but undetected prostate cancer or for patients undergoing surveillance for known low-risk prostate cancer. Since prostate cancer is often multi-focal and presents with multiple lesions of varying risk, it is important to identify the lesions that harbor the greatest malignant potential. Accurate identification of clinically significant cancer and avoidance of clinically insignificant cancer is the centerpiece of modern prostate cancer diagnosis. The use of advanced imaging to inform placement of biopsy needles promises to greatly minimize the uncertainty associated with prostate cancer care."
Related Links:
University of Michigan
Latest Nuclear Medicine News
- New PET Agent Rapidly and Accurately Visualizes Lesions in Clear Cell Renal Cell Carcinoma Patients
- New Imaging Technique Monitors Inflammation Disorders without Radiation Exposure
- New SPECT/CT Technique Could Change Imaging Practices and Increase Patient Access
- New Radiotheranostic System Detects and Treats Ovarian Cancer Noninvasively
- AI System Automatically and Reliably Detects Cardiac Amyloidosis Using Scintigraphy Imaging
- Early 30-Minute Dynamic FDG-PET Acquisition Could Halve Lung Scan Times
- New Method for Triggering and Imaging Seizures to Help Guide Epilepsy Surgery
- Radioguided Surgery Accurately Detects and Removes Metastatic Lymph Nodes in Prostate Cancer Patients
- New PET Tracer Detects Inflammatory Arthritis Before Symptoms Appear
- Novel PET Tracer Enhances Lesion Detection in Medullary Thyroid Cancer
- Targeted Therapy Delivers Radiation Directly To Cells in Hard-To-Treat Cancers
- New PET Tracer Noninvasively Identifies Cancer Gene Mutation for More Precise Diagnosis
- Algorithm Predicts Prostate Cancer Recurrence in Patients Treated by Radiation Therapy
- Novel PET Imaging Tracer Noninvasively Identifies Cancer Gene Mutation for More Precise Diagnosis
- Ultrafast Laser Technology to Improve Cancer Treatment
- Low-Dose Radiation Therapy Demonstrates Potential for Treatment of Heart Failure